Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Homecare Assistance Grant
Through the Homecare Assistance Grant, MS Focus provides homecare, caregiver respite, and...
/Get-Help/MSF-Programs-Grants/Homecare-Assistance-Grant
Shop
Privacy
Terms of Use
Site Map
Simple blood test may predict MRI disease activity in MS
December 14, 2017
According to a new study, a blood test to monitor a nerve protein in the blood of people with multiple sclerosis may help predict whether disease activity is flaring up. The nerve protein, called neurofilament light chain, is a component of nerve cells and can be detected in the blood stream and spinal fluid when nerve cells die. The researchers suggest blood tests for this nerve protein may be an effective way to monitor disease activity and how well the treatment is working.
For the two-year study, researchers at the University of Bergen, Norway, enrolled 85 people who had relapsing-remitting MS for an average of two years. During the first six months, participants did not receive disease-modifying treatment. For the remaining 18 months, they were all treated with interferon-beta 1a. For the first nine months, participants had monthly magnetic resonance imaging scans. They then had MRI scans again at year one and year two. Blood samples were also taken at the beginning of the study, at three and six months, as well as at year one and year two.
Researchers found that nerve protein levels in the blood were higher when MRI detected new T1 and T2 lesions. Those with new T1 lesions had 37.3 picograms per milliliter of the nerve protein in their blood compared with 28 pg/ml for people without new T1 lesions. Those with new T2 lesions had 37.3 pg/ml of nerve protein in the blood compared with 27.7 pg/ml for those without new T2 lesions. Increased nerve protein levels were present for a three-month time period during the development of new lesions. Nerve protein levels also fell when treatment with interferon-beta 1a treatment began. The researchers found that an increase of 10 pg/ml in a person was associated with a 48-percent increased risk of developing a new T1 lesion and 62-percent increased risk of a new T2 lesion.
The study was published in the online issue of
Neurology
,
Neuroimmunology and Neuroinflammation
, an official journal of the American Academy of Neurology.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more